This came after Alkem Laboratories presented BE study protocol vide no. BIOS/2024/128, Version No. 01, Dated 17.07.2024 and ...

Viking Therapeutics inks broad manufacturing pact with CordenPharma to support commercialization of VK2735: San Diego Wednesday, March 12, 2025, 17:00 Hrs [IST] Viking Therapeutic ...

This long-term agreement will help support the commercialization of VK2735.

Beyond type 2 diabetes and weight loss, GLP-1 agonists can also help lower blood pressure, improve lipid disorders, reduce ...

VK2735, the company's dual agonist of the glucagon-like peptide 1 (GLP-1 ... 2 VENTURE-Oral Dosing Trial of VK2735 dosed as an oral tablet once daily for 13 weeks. Additionally, the company ...

On February 21, 2025, the US Food and Drug Administration (FDA) revised its shortage categorization of semaglutide, a glucagon-like peptide 1 ...

WHEN doctors told her she was overweight, former Big Brother star Narinder Kaur took a decision that could have claimed her ...

"The glucagon-like peptide (GLP-1 ... except one that is available in tablet form (Rybelsus). A few generic and brand names of GLP-1 agonists, according to the Johns Hopkins Patient Guide ...

“The third quarter of 2024 drew consistent attention to our pivotal-staged clinical asset, EB613, the first oral PTH(1-34) tablet treatment ... dual agonist GLP-1/glucagon peptide.